Small Animal Imaging (In-Vivo) Market report, published by Allied Market Research, forecasts that the global market is expected to garner $2.1 Billion by 2020, registering a CAGR of 9.1% during the forecast period 2014 to 2020. Optical imaging modality is and would continue to be the most preferred imaging technology for clinical research organizations (CROs) through 2020, largely due to high sensitivity, economic pricing and a broad scope of applications. Such factors would eventually push the optical imaging technology segment to contribute about 40% of the global small animal imaging market revenue by 2020.
Rising number of pre-clinical research, increasing investments by the CROs in the research activities, a growing number of multi-functional pre-clinical imaging and technological advancements, namely combination of high resolution MRI with other imaging modalities are the few factors empowering the global market. Spatial resolution multimodal imaging, Cerenkov Bioluminescence Imaging and real time storage multimodal imaging system collectively contribute to the significance of small animal imaging (in-vivo) systems in the drug development and translational research. These technologies exemplify the recent and unique advancements in the field of diagnostic devices, amplifying the scope of applications in pre-clinical as well as clinical research. However, stringent regulatory impositions coupled with inadequate reimbursement policies would restrain the market growth to a certain extent. However, faster commercialization of cost-efficient devices would ease the negative influence of restraints and fuel the market growth, primarily across the developing regions.
Most common small animal in-vivo imaging devices used in pre-clinical applications are micro-MRI, optical imaging, and nuclear imaging modalities, namely as the micro-PET and micro-SPECT, micro-ultrasound, micro-CT and optical imaging. Owing to the versatility of imaging modalities, they are used in a variety of biomedical applications such as monitoring treatment responses, assessing bio-distribution patterns, cancer cell detection, and longitudinal as well as epigenetic studies. Routine application of imaging in bio-distribution and drug monitoring together contributed to ~60% of the market in 2013. Existing potential growth opportunities in oncological research would make the cancer cell detection application market lucrative and thus, would emerge as a fastest growing application market segment during the forecast period.
Key Findings of Small Animal Imaging (In-Vivo) Market:
- Micro MRI, nuclear imaging, and micro CT modalities collectively accounted for about 52% of the revenue generated in 2013
- Optical imaging and micro-MRI technology segments would collectively command over 2/3rdof the market revenue during the forecast period
- Cancer cell detection application market segment would grow at a higherrate during the forecast period, owing to the rising prevalence rate of cancer across the world
Technologies have a notable impact on the small animal imaging market and manufacturers with novel technology rights are holding substantial market share. Advent in these novel technologies lead sto launch of new and advance product lines in thesmall animal imaging market. To gain the maximum market share, key leaders of the small animal in-vivo imaging market have adopted acquisition as a strategy, which has proved to be the most successful in this market. Key companies profiled in this report are, Thermo Fisher Scientific, Siemens AG, Mediso Medical Imaging Systems, Life Technologies Corporation, Promega Corporation, Miltenyi Biotech, Bruker Corporation, FujiFilm Holding Corporation, PerkinElmer Inc., and Aspect Imaging Ltd.